SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Aug. 30, 2018--
Veracyte,
Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson,
chairman and chief executive officer, will present at the Morgan Stanley
16th Annual Global Healthcare Conference on Thursday, September 13, 2018
at 2:55 p.m. Eastern Time in New York City.
The live webcast of the presentation and a subsequent replay may be
accessed by visiting Veracyte's website at http://investor.veracyte.com.
The replay of the webcast will be available shortly after the conclusion
of the presentation and archived on the company's website for 90 days
following the presentation.
About Veracyte
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that
improves patient care by providing trustworthy and actionable answers to
challenging clinical questions. The company's products uniquely combine
advanced genomic technology, clinical science and machine learning to
provide answers that give physicians and patients a clear path forward,
informing both diagnosis and treatment decisions without the need for
costly, risky surgeries that are often unnecessary. Since its founding
in 2008, Veracyte has commercialized three genomic tests, which are
transforming the diagnosis of thyroid cancer, lung cancer and idiopathic
pulmonary fibrosis and collectively target a $2 billion market
opportunity. Veracyte is based in South San Francisco, California. For
more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma
logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005251/en/
Source: Veracyte, Inc.
Veracyte Media & Investor Contact:
Angie McCabe,
650-243-6371
VP, Investor Relations & Corporate Communications
angie@veracyte.com